BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19055662)

  • 21. Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy.
    Yakushijin Y; Shikata H; Takaoka I; Horikawa T; Takeuchi K; Yamanouchi J; Azuma T; Narumi H; Hato T; Yasukawa M
    Int J Clin Oncol; 2011 Apr; 16(2):118-24. PubMed ID: 20924633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
    Morrison VA; Weller EA; Habermann TM; Li S; Fisher RI; Cheson BD; Peterson BA
    Leuk Lymphoma; 2017 Aug; 58(8):1814-1822. PubMed ID: 27967294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP.
    Shikata H; Yakushijin Y; Yamanouchi J; Azuma T; Yasukawa M
    Int J Clin Oncol; 2014 Feb; 19(1):178-85. PubMed ID: 23380958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy.
    Kim T; Choi SH; Kim SH; Jeong JY; Woo JH; Kim YS; Sung H; Kim MN; Yoon DH; Suh C; Lee SO
    Ann Hematol; 2013 Jan; 92(2):231-8. PubMed ID: 23053189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
    Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
    Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
    Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB
    Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas.
    Silvestri F; Velisig M; Fanin R; Virgolini L; Zaja F; Barillari G; Baccarani M
    Leuk Lymphoma; 1995 Feb; 16(5-6):465-70. PubMed ID: 7540461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
    Morrison VA; Picozzi V; Scott S; Pohlman B; Dickman E; Lee M; Lawless G; Kerr R; Caggiano V; Delgado D; Fridman M; Ford J; Carter WB;
    Clin Lymphoma; 2001 Jun; 2(1):47-56. PubMed ID: 11707870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis.
    Kim YR; Kim SJ; Park Y; Oh SY; Yun HJ; Mun YC; Kim JS;
    Korean J Intern Med; 2021 Sep; 36(5):1181-1189. PubMed ID: 34265889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
    Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.
    Jeon SY; Yhim HY; Kim HS; Kim JA; Yang DH; Kwak JY
    Korean J Intern Med; 2018 Nov; 33(6):1169-1181. PubMed ID: 29295612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study.
    Pettengell R; Schwenkglenks M; Leonard R; Bosly A; Paridaens R; Constenla M; Szucs TD; Jackisch C;
    Support Care Cancer; 2008 Nov; 16(11):1299-309. PubMed ID: 18351398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
    Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
    J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.
    Reagan JL; Rosmarin A; Butera JN; Nadeem A; Schiffman FJ; Sikov WM; Winer E; Mega AE
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1075-80. PubMed ID: 21761371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
    Visani G; Guiducci B; D'Adamo F; Mele A; Nicolini G; Leopardi G; Sparaventi G; Barulli S; Malerba L; Isidori A; Malagola M; Piccaluga PP
    Leuk Lymphoma; 2005 Mar; 46(3):477-9. PubMed ID: 15621843
    [No Abstract]   [Full Text] [Related]  

  • 39. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
    Sparano JA; Lee JY; Kaplan LD; Levine AM; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Von Roenn J; Dezube BJ; Remick SC; Shah MH; Leichman L; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R;
    Blood; 2010 Apr; 115(15):3008-16. PubMed ID: 20023215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.